Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5189175 | 0.87 | MAPT (0.41) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL4194009 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL16324474 | 0.82 | ALDH1A1 (0.68) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL12901284 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL31437774 | 0.77 | ALDH1A1 (0.49) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL3466332 | 0.75 | ALDH1A1 (0.46) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL30576258 | 0.75 | ALDH1A1 (0.46) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL29118209 | 0.74 | ALDH1A1 (0.45) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL28574994 | 0.74 | ALDH1A1 (0.49) | ALDH1A1MITFSOS1PKMPOLB | |
| SCHEMBL5188985 | 0.74 | ALDH1A1 (0.40) | ALDH1A1MITFSOS1PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644599-B1 | Method for preparing a 2-halo-4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2644599-A1 | Method for preparing 1-substituted-4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-05-24 | — | — | US | disclosed |
| US-8129544-B2 | Preparation of 4-nitroimidazoles that are 2-substituted with a halo or optionally oxidized phenylthio group and 1-substituted with hydrogen, an oxiranylmethyl-, or a phenyl- group; dehalogenation, reduction, nitration, rearrangement | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7807843-B2 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090082575-A1 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-08-21 | — | — | US | disclosed |
| US-7368579-B2 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO. LTD. | 2008-04-24 | — | — | US | disclosed |
| CN-101027287-A | Method for producing 2-chloro-4-nitroimidazole | OTSUKA PHARMA CO LTD (JP) | 2007-08-29 | — | — | CN | disclosed |
| CN-1326840-C | 1-substituted-4-nitroimidazole compounds and process for preparing same | OTSUKA PHARMA CO LTD (JP) | 2007-07-18 | — | — | CN | disclosed |
| EP-1794132-A2 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| WO-2006035960-A2 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| CN-1692103-A | 1-substituted-4-nitroimidazole compounds and process for preparing same | OTSUKA PHARMA CO LTD (JP) | 2005-11-02 | — | — | CN | disclosed |
| EP-1553088-A1 | 1-SUBSTITUTED 4-NITROIMIDAZOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Otsuka Pharmaceutical Company, Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082575-A1 | PROCESS FOR PRODUCTION OF 2-CHLORO-4-NITROIMIDAZOLE | COX4I1, MT-ND4, MT-ND4L | ALDH1A1 430/4885MITF 4635/4885SOS1 4042/4885 |
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | CBR1, CBR3, DCXR | ALDH1A1 836/4885MITF 4272/4885SOS1 2129/4885 |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | CBR1, CBR3, DCXR | ALDH1A1 780/4885MITF 3941/4885SOS1 2493/4885 |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | ALDH1A1 836/4885MITF 4272/4885SOS1 2129/4885 |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | ALDH1A1 836/4885MITF 4272/4885SOS1 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.